Table 1 Summary of clinical characteristics between two CF groups ≤18 years and >18 years
From: Persistence of Candida dubliniensis and lung function in patients with cystic fibrosis
Parameters | ≤18 years (N = 38) | >18 years (N = 14) | P |
|---|---|---|---|
N(%) | N(%) | ||
Sex/male | 21 (55.3) | 9 (64.3) | 0.559 |
No. of CF patients with CFTR 1234 V mutation | 30 (78.9) | 14 (100%) | 0.062 |
No. of CF patients with other CFTR mutation | 8 (21.1) | 0 | 0.130 |
No. of CF patients with pancreatic sufficiency | 30 (78.9) | 12 (85.7) | 0.583 |
No. of CF patients with CF related diabetes | 1 (2.6) | 4 (28.6) | 0.005 |
Nebulized tobramycin use | 14 (36.8) | 11 (78.6) | 0.008 |
Oral zithromax use | 1 (2.6) | 8 (57.1) | <0.001 |
Nebulized pulmozyme use | 24 (63.2) | 13 (92.9) | 0.036 |
Nebulized hypertonic saline use | 9 (23.7) | 7 (50) | 0.142 |